- AU$188.17m
- AU$152.54m
- AU$11.34m
- 56
- 20
- 52
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.69 | ||
| Price to Tang. Book | 5.28 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 17.97 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.83% | ||
| Return on Equity | -42.36% | ||
| Operating Margin | -185.2% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 4.16 | 5.74 | 8.41 | 10.57 | 11.34 | 11.58 | 20.18 | 27.87% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ImpediMed Limited is an Australia-based medical software technology company. The Company is engaged in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services with a focus on the early detection of lymphoedema and heart failure. It measures, monitors and manages fluid status and tissue composition using BIS. The Company’s SOZO digital health platform uses BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its SFB7 measures fluid status and tissue composition for clinical and research applications. It offers ImpediVET, a single-channel, tetrapolar BIS device that measures fluid status and tissue composition for veterinary applications from laboratory research to clinic. SOZO applications include L-Dex Analysis for Lymphedema, BodyComp Analysis, Segmental BodyComp analysis, and HF-Dex analysis for heart failure.
Directors
- Donald Williams CHM (62)
- Richard Carreon CEO
- Timothy Cruickshank CFO
- Michael Bassett SVP
- David Adams SVP
- Catherine Kingsford SVP
- Dennis Schlaht SVP
- Shashi Tripathi CTO
- Nancy Deisinger VPR
- Frank Vicini OTH
- Leanne Ralph SEC
- David Anderson NID
- Judith Downes NID
- Robert Graham NID
- Amit Patel NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 27th, 1999
- Public Since
- October 24th, 2007
- No. of Shareholders
- 5,191
- No. of Employees
- 76
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 2,023,307,922
- Address
- Pinkenba, U 1 50 Parker Ct, BRISBANE, 4008
- Web
- https://www.impedimed.com
- Phone
- +61 738603700
- Contact
- Hannah Howlett
- Auditors
- Ernst & Young
Upcoming Events for IPD
Similar to IPD
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Allegra Medical Technologies
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
FAQ
What is the ImpediMed share price?
As of Today at 19:11 UTC, shares in ImpediMed are trading at AU$0.09. This share price information is delayed by 15 minutes.
How has the ImpediMed share price performed this year?
Shares in ImpediMed last closed at AU$0.09 and the price had moved by -22.5% over the past 365 days. In terms of relative price strength the ImpediMed share price has underperformed the ASX All Ordinaries Index by -25.87% over the past year.
What are the analyst and broker recommendations for ImpediMed?
The overall consensus recommendation for ImpediMed is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the ImpediMed dividend yield?
ImpediMed does not currently pay a dividend.
Does ImpediMed pay a dividend?
ImpediMed does not currently pay a dividend.
When does ImpediMed next pay dividends?
ImpediMed does not currently pay a dividend.
How do I buy ImpediMed shares?
To buy shares in ImpediMed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ImpediMed?
As of the previous close price of AU$0.09, shares in ImpediMed had a market capitalisation of AU$188.17m.
Where are ImpediMed shares listed?
Here are the trading details for ImpediMed:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: IPD
What kind of share is ImpediMed?
Based on an overall assessment of its quality, value and momentum ImpediMed is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ImpediMed share price forecast for 2024?
The analyst consensus target price for shares in ImpediMed is AU$0.18. That is 88.17% above the last closing price of AU$0.09.
Analysts covering ImpediMed currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.01 for the next financial year.
What is the trend in the ImpediMed share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ImpediMed. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -31.03%.
As of the last closing price of AU$0.09, shares in ImpediMed were trading -33.8% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ImpediMed PE Ratio?
The ImpediMed PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ImpediMed?
ImpediMed's management team is headed by:
- Donald Williams - CHM
- Richard Carreon - CEO
- Timothy Cruickshank - CFO
- Michael Bassett - SVP
- David Adams - SVP
- Catherine Kingsford - SVP
- Dennis Schlaht - SVP
- Shashi Tripathi - CTO
- Nancy Deisinger - VPR
- Frank Vicini - OTH
- Leanne Ralph - SEC
- David Anderson - NID
- Judith Downes - NID
- Robert Graham - NID
- Amit Patel - NID